Traphagen Investment Advisors LLC Increases Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Traphagen Investment Advisors LLC boosted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 11.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 770 shares of the biopharmaceutical company’s stock after acquiring an additional 82 shares during the period. Traphagen Investment Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $488,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of REGN. Pamalican Asset Management Ltd purchased a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at approximately $4,915,000. Intact Investment Management Inc. purchased a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at approximately $356,000. Rhenman & Partners Asset Management AB grew its stake in shares of Regeneron Pharmaceuticals by 11.4% in the 4th quarter. Rhenman & Partners Asset Management AB now owns 43,457 shares of the biopharmaceutical company’s stock valued at $30,956,000 after buying an additional 4,457 shares during the period. Fagan Associates Inc. grew its stake in shares of Regeneron Pharmaceuticals by 42.2% in the 4th quarter. Fagan Associates Inc. now owns 12,923 shares of the biopharmaceutical company’s stock valued at $9,205,000 after buying an additional 3,832 shares during the period. Finally, GAMMA Investing LLC grew its stake in shares of Regeneron Pharmaceuticals by 89,825.0% in the 1st quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company’s stock valued at $517,291,000 after buying an additional 814,713 shares during the period. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Up 1.4%

Shares of NASDAQ:REGN opened at $529.24 on Monday. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $1,211.20. The company’s 50 day moving average is $563.19 and its two-hundred day moving average is $648.52. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The company has a market cap of $57.14 billion, a PE ratio of 13.83, a P/E/G ratio of 2.34 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing analysts’ consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm had revenue of $3.03 billion during the quarter, compared to analysts’ expectations of $3.40 billion. During the same period in the prior year, the company posted $9.55 earnings per share. The company’s revenue for the quarter was down 3.7% on a year-over-year basis. Equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th were given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.67%. The ex-dividend date was Tuesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio is presently 8.96%.

Analyst Ratings Changes

REGN has been the subject of several analyst reports. Cantor Fitzgerald initiated coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, April 22nd. They issued an “overweight” rating and a $695.00 price target for the company. Robert W. Baird dropped their price target on shares of Regeneron Pharmaceuticals from $759.00 to $652.00 and set a “neutral” rating for the company in a research note on Friday, April 25th. Guggenheim reissued a “buy” rating on shares of Regeneron Pharmaceuticals in a research note on Friday, May 30th. Wells Fargo & Company lowered shares of Regeneron Pharmaceuticals from an “overweight” rating to an “equal weight” rating and decreased their price objective for the stock from $700.00 to $580.00 in a report on Friday, May 30th. Finally, BMO Capital Markets decreased their price objective on shares of Regeneron Pharmaceuticals from $800.00 to $600.00 and set an “outperform” rating on the stock in a report on Monday, June 2nd. One analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have issued a buy rating and three have given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $836.48.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.